NEWARK, Del. -- (BUSINESS WIRE) -- New technologies to produce vaccines more safely, quickly and economically than traditional approaches are featured at the New Vaccines 2014: How New Science is Shaping Regulatory and Business Decisions international scientific conference, being held March 24-26 at Theater N in Wilmington, Delaware.
Keynote Speaker Dr. Michael Kurilla, M.D., Ph.D., Director of the Office of Biodefense, Research Resources, and Translational Research as well as Associate Director for Biodefense Product Development for the National Institute of Allergy and Infectious Diseases (NIAID), will lead the 3-day conference with a presentation titled “Vaccines & Vaccinations.” His primary role at NIAID is to provide overall institute coordination for product development of medical countermeasures against bioterror threats and other emerging infectious diseases.
More than 40 world-leading scientists will present on how these advances significantly impact responsiveness to life-threatening disease threats. Over the 3-day conference, the following topics will be covered: Biomanufacturing and Product Development; Molecular Designs and Formulations; and How New Science is Shaping Regulatory and Business Making Decisions.
“With the growing global demand for vaccines and other biologics, development of technologies for making safer and better products remains to be critical. At this conference we will hear the latest advancements in science impacting pharmaceutical product development,” Fraunhofer USA CMB Executive Director Dr. Vidadi Yusibov added, “and anticipate this exchange of information to facilitate collaborations that will lead to the creation of new knowledge and capabilities.”
Anticipated attendees include scientists, business leaders and regulatory agency representatives from around the world. The annual scientific conference provides an opportunity for attendees to exchange information on bringing life-saving vaccines and therapeutics to market more quickly through innovative manufacturing processes.
The event is hosted by Delaware-based vaccine production pioneer, Fraunhofer USA Center for Molecular Biotechnology (FHCMB) and is conducted in cooperation with the International Association for Biological Standardization (IABS), Geneva, Switzerland. Other conference sponsors are IBio, Inc., Protein Sciences Corporation, Vedantra Pharmaceuticals and the IIT Research Institute (IITRI).
With a focus on understanding the impact of these new technologies, additional topics to be discussed include next generation products, production methods and regulatory considerations for new technologies.
To register, please visit www.ntnv.org by Friday, March 21.
About Fraunhofer USA Center for Molecular Biotechnology
Fraunhofer USA CMB, a division of Fraunhofer USA, Inc., is a not-for-profit research organization whose mission is to develop safe and effective vaccines targeting infectious diseases and autoimmune disorders. CMB’s technology provides a safe, rapid and economical alternative for vaccine production. The Center conducts research in biotechnology, utilizing new, cutting edge technologies to assist the diagnosis, prevention and treatment of human and animal diseases. The Center houses individuals with expertise and excellence in virology, molecular biology, immunology, , protein engineering, biochemistry, GMP production and regulatory processes. Fraunhofer USA, Inc. is a subsidiary of Fraunhofer Gesellschaft, Europe’s largest organization for applied research. Further information is available at www.fhcmb.org.
For press registration to attend the workshop or for additional information, contact: Dale Ervin, Fraunhofer USA CMB at 302-369-3034 or email@example.com.